

(<http://aphanet.org>)

[Home](#) > Treatment of peripheral T-cell lymphoma

Generic Name:

Romidepsin

Trade Name:

Istodax

Company:

Celgene

Notes:

According to a [press release](#) by Celgene, FDA approval of romidepsin was based on data from two studies demonstrating an improved response rate in patients with PTCL. Improvements in hard clinical outcomes, such as improvement in overall survival, have not been demonstrated. Romidespin was previously approved for treatment of cutaneous T-cell lymphoma in patients who have received at least one prior systemic therapy.

Medication Monitor Categories:

[Supplemental Approvals](#)

Use:

Treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy

Source URL: <http://aphanet.org/supplemental-approvals/treatment-peripheral-t-cell-lymphoma>